Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Biomarkers in Oncology | Access & Reimbursment | US | NSCLC, Bladder Cancer, and Gastric / GEJ Adenocarcinoma | 2021

Login to access report north_east
Contact sales account_box

Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in indications such as non-small-cell lung cancer (NSCLC) and bladder cancer and is playing an increasingly important role in indications such as gastric and gastroesophageal junction (GEJ) adenocarcinoma. Although biomarker-associated therapies offer the advantage of selecting the patients most likely to respond to treatment, these therapies are premium-priced and often subject to payer restrictions and cost-containment strategies.

QUESTIONS ANSWERED

· What factors largely influence payers’ reimbursement decisions for biomarker-driven therapies in NSCLC, bladder cancer, and gastric and GEJ adenocarcinoma? What restrictions do they impose?

· Do access and reimbursement challenges differ by indication, and how well established are biomarkers in each indication?

· What impact do reimbursement and cost have in oncologists’ decisions to prescribe biomarker-driven therapies?

· What are payer opinions of emerging agents, and how will oncologists’ prescribing patterns change with the launch of new therapies?

· What factors influence reimbursement and access of companion biomarker tests?

GEOGRAPHY: United States.

PRIMARY RESEARCH: Survey of 100 U.S. medical oncologists and 30 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs/MDs).

KEY DRUGS COVERED:

Tagrisso, Tarceva, Gilotrif, Iressa, Vizimpro, Rybrevant, Lumakras, Tabrecta, Tepmetko, Retevmo, Gavreto, Keytruda, Tecentriq, Balversa, Opdivo, and Enhertu

CONTENT HIGHLIGHTS:

  • Reimbursement and contracting
  • Access and prescribing
  • Opportunities and challenges for emerging therapies
  • Disease-specific special topic
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
north_east
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used in parallel to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via…
north_east
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
north_east
Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…
north_east
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east